<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128435</url>
  </required_header>
  <id_info>
    <org_study_id>200629</org_study_id>
    <nct_id>NCT05128435</nct_id>
  </id_info>
  <brief_title>Coronavirus Pediatric Serological Study</brief_title>
  <acronym>CoPSS</acronym>
  <official_title>Coronavirus Pediatric Serological Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Saint Pierre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Saint Pierre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Coronavirus Pediatric Serological Study's aim is to provide a better insight of&#xD;
      children's immune response after SARS-CoV-2 infection.&#xD;
&#xD;
      Serological tests were conducted on blood samples taken 3 to 5 months after the children's&#xD;
      viral infection.&#xD;
&#xD;
      The study was performed in collaboration with the Institute of Medical Immunology, were&#xD;
      antibody levels were measured and immunoglobulin subclasses profiles were studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hospital laboratory provided us the list of children under 15 years old tested for&#xD;
      SARS-CoV-2 in Saint-Pierre Hospital (Brussels) by PCR on nasopharyngeal swab between March 1&#xD;
      2020 and December 31 2020.&#xD;
&#xD;
      The medical files of all children that were tested positive for SARS-CoV-2 were reviewed and&#xD;
      clinical information was collected.&#xD;
&#xD;
      For each positive child, the family was contacted by phone 3 months after the proven viral&#xD;
      infection in order to ask permission to take a single blood test.&#xD;
&#xD;
      Covid19 serologies were performed in the hospital laboratory, and blood samples were then&#xD;
      sent to the Institute of Medical Immunology, were antibody levels and immunoglobulin&#xD;
      subclasses were studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Actual">May 31, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV-2 antibody levels in asymptomatic patients</measure>
    <time_frame>3 to 5 months after SARS-CoV-2 infection</time_frame>
    <description>Measurement of SARS-CoV-2 IgG (total and subclasses), IgA (total and subclasses) and IgM levels in the sera of children who did not show any symptoms at the time of the viral infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 antibody levels in mildly symptomatic patients</measure>
    <time_frame>3 to 5 months after SARS-CoV-2 infection</time_frame>
    <description>Measurement of SARS-CoV-2 IgG (total and subclasses), IgA (total and subclasses) and IgM levels in the sera of children presenting mild symptoms at the time of the viral infection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SARS-CoV-2 antibody levels in hospitalized patients</measure>
    <time_frame>3 to 5 months after SARS-CoV-2 infection</time_frame>
    <description>Measurement of SARS-CoV-2 IgG (total and subclasses), IgA (total and subclasses) and IgM levels in the sera of children who required an hospitalisation at the time of the viral infection</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <arm_group>
    <arm_group_label>Positive Children</arm_group_label>
    <description>Children under 15 years old tested positive for SARS-CoV-2 by PCR on nasopharyngeal swab</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample taken 3 to 5 months after the infection</description>
    <arm_group_label>Positive Children</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children under 15 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Tested positive for SARS-CoV-2 by PCR on naso-pharyngeal swab performed in Saint-Pierre&#xD;
        Hospital (Brussels) between March 1 2020 and December 31 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  /&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>179 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saint-Pierre Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Saint Pierre</investigator_affiliation>
    <investigator_full_name>Lisa Tomasi</investigator_full_name>
    <investigator_title>Doctor (pediatrician)</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Immune response</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

